Advertisement

Applied Health Economics and Health Policy

, Volume 10, Issue 4, pp 227–234 | Cite as

Economic Consequences of the Demography of MRSA Patients and the Impact of Broad-Spectrum Antimicrobials

  • Klaus KaierEmail author
  • S. Moog
Short Communication

Abstract

Background: Studies have determined the societal impact of methicillin-resistant Staphylococcus aureus (MRSA) by modelling its impact on labour supply and productivity. In addition, most of the studies on the topic conclude that the problem of resistance should be counteracted on the macro level by reducing overall antibacterial consumption.

Objective: Two major questions have been raised in the present work. Firstly, is MRSA impairing labour supply and productivity? Secondly, is it the overall use of antibacterials that may be seen as crucial to the spread of MRSA infections?

Methods: The age distribution of MRSA patients is compared with the age distribution of the entire patient population at a German teaching hospital. In addition, the age distribution of MRSA patients was applied to the age distribution of the German population in the year 2050 in order to identify the effects of the double-ageing process on the spread of MRSA. Furthermore, recent epidemiological studies were reviewed on the impact of overall antibacterial consumption on MRSA infection rates.

Results: Based on available data, we show that patients infected or colonized with MRSA are, for the most part, beyond retirement age and thus not responsible for changes in labour supply or productivity. Application of age distribution of MRSA patients to the age distribution of the German population in the year 2050 gives a 24% increase in the number of MRSA cases to a total of 182 778 due to an ageing population. In addition, we show that a 32% reduction in the cost of MRSA to the German healthcare system could be reached if use of fluoroquinolones and third-generation cephalosporins was reduced by just 10% and, correspondingly, use of antiseptics for hand disinfection was increased by 10%.

Conclusions: MRSA is a phenomenon that, to a larger degree, affects the elderly population rather than the labour force. When it comes to policy options to counteract MRSA on the macro level, most economic research on the topic is biased in assuming that the overall use of antibacterials is responsible for the spread of MRSA infections.

Keywords

Labour Supply German Population German Hospital Hand Disinfection Attributable Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thank Deborah Lawrie-Blum for her help in preparing the manuscript. Furthermore, we thank the entire Division of Infection Control at University Medical Center Freiburg for efforts in data collection.

Research by Klaus Kaier on the economic impacts of antibiotic resistance is currently supported by the European Commission (Project IMPLEMENT, Project commissioned by DG Health and Consumers, Grant Agreement No. 20091107.

The authors have no conflicts of interest that are directly relevant to the content of this article.

CM and KK contributed equally to the development of the study to the calculation of results. In addition, KK was responsible for the preparation of the manuscript and acts as a guarantor for the overall content.

References

  1. 1.
    Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003 Jun 1; 36(11): 1433–7PubMedCrossRefGoogle Scholar
  2. 2.
    Kaier Wilson Chalkley M, et al. Health and economic impacts of antibiotic resistance in european hospitals: outlook on the BURDEN project. Infection 2008 Sep 15; 36(5): 492–4PubMedCrossRefGoogle Scholar
  3. 3.
    Smith RD, Yago M, Millar M, et al. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J Health Econ 2005 Nov; 24(6): 1055–75PubMedCrossRefGoogle Scholar
  4. 4.
    Smith RD, Yago M, Millar M, et al. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy 2006; 5(1): 55–65PubMedCrossRefGoogle Scholar
  5. 5.
    Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007; 25(9): 751–68PubMedCrossRefGoogle Scholar
  6. 6.
    Paladino JA, Sunderlin JL, Price CS, et al. Economic consequences of antimicrobial resistance. Surg Infect 2002; 3(3): 259–67CrossRefGoogle Scholar
  7. 7.
    Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6(5): 751–63PubMedCrossRefGoogle Scholar
  8. 8.
    Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ 2009 Jan 1; 10(3): 287–97PubMedCrossRefGoogle Scholar
  9. 9.
    Kaier K, Frank U. Measuring the externality of antibacterial use from promoting antimicrobial resistance. Pharmacoeconomics 2010; 28(12): 1123–8PubMedCrossRefGoogle Scholar
  10. 10.
    Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med 1998 Jan; 46(1): 29–38PubMedCrossRefGoogle Scholar
  11. 11.
    Fischer Laxminarayan R. Sequential development and exploitation of an exhaustible resource: do monopoly rights promote conservation? J Environ Econ Manage 2005 May; 49(3): 500–15CrossRefGoogle Scholar
  12. 12.
    Horowitz JB, Moehring HB. How property rights and patents affect antibiotic resistance. Health Econ 2004 Jun; 13(6): 575–83PubMedCrossRefGoogle Scholar
  13. 13.
    Kambou G, Devarajan S, Over M. The economic impact of AIDS in an African country: simulations with a computable general equilibrium model of Cameroon. J Afr Econ 1992; 1(1): 109–30Google Scholar
  14. 14.
    Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002; 415(6872): 680–5PubMedCrossRefGoogle Scholar
  15. 15.
    Barlow R. The economic effects of malaria eradication. Am Econ Rev 1967; 57(2): 130–48Google Scholar
  16. 16.
    Bloom DE, Mahal AS. Does the AIDS epidemic threaten economic growth? J Econometr 1997; 77(1): 105–24CrossRefGoogle Scholar
  17. 17.
    Witte W. Community-acquired methicillin-resistant Staphylococcus aureus: what do we need to know? Clin Microbiol Infect 2009; 15: 17–25PubMedCrossRefGoogle Scholar
  18. 18.
    Federal Statistical Office. Bevölkerung und Erwerbstätigkeit 2008. Fachserie 1, Reihe 1.3 2010 [online]. Available from URL: https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsstand/Bevoelkerungsfortschreibung2010130087004.pdf [Accessed 2012 Apr 19]
  19. 19.
    German Nosocomial Infection Surveillance System. Reference data MRSA-KISS [online]. Available from URL: http://www.nrz-hygiene.de [Accessed 2012 Apr 5]
  20. 20.
    Federal Statistical Office. Grunddaten der Krankenhäuser 2008. Fachserie 12, Reihe 6.1.1 2010 [online]. Available from URL: https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/GrunddatenKrankenhaeuser2120611087004.pdf [Accessed 2012 Apr 19]
  21. 21.
    Levy SB. The antibiotic paradox: how miracle drugs are destroying the miracle. New York, London: Plenum Press, 1992Google Scholar
  22. 22.
    Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996 May; 5(3): 217–26PubMedCrossRefGoogle Scholar
  23. 23.
    Elbasha EH. Deadweight loss of bacterial resistance due to overtreatment. Health Econ 2003 Feb; 12(2): 125–38PubMedCrossRefGoogle Scholar
  24. 24.
    Phelps CE. Bug/drug resistance: sometimes less is more. Med Care 1989 Feb; 27(2): 194–203PubMedCrossRefGoogle Scholar
  25. 25.
    Herrmann M. Monopoly pricing of an antibiotic subject to bacterial resistance. J Health Econ 2010 Jan; 29(1): 137–50PubMedCrossRefGoogle Scholar
  26. 26.
    Rudholm N. Economic implications of antibiotic resistance in a global economy. J Health Econ 2002 Nov; 21(6): 1071–83PubMedCrossRefGoogle Scholar
  27. 27.
    Aldeyab MA, Monnet DL, Lopez-Lozano JM, et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008 May 7; 62(3): 593–600PubMedCrossRefGoogle Scholar
  28. 28.
    Kaier K, Hagist C, Frank U, et al. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30(4): 346–53PubMedCrossRefGoogle Scholar
  29. 29.
    Kaier K, Frank U. An econometric view of the dynamic relationship between antibiotic consumption, hand disinfection and methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2009; 63(3): 630–1PubMedCrossRefGoogle Scholar
  30. 30.
    Vernaz N, Sax H, Pittet D, et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008 May 8; 62(3): 601–7PubMedCrossRefGoogle Scholar
  31. 31.
    Organisation for Economic Cooperation and Development (OECD). OECD health data, 2006. Paris: OECD, 2010Google Scholar
  32. 32.
    Simonsen L, Conn LA, Pinner RW, et al. Trends in infectious disease hospitalizations in the United States, 1980–1994. Arch Intern Med 1998; 158(17): 1923–8PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen ML. Changing patterns of infectious disease. Nature 2000; 406(6797): 762–7PubMedCrossRefGoogle Scholar
  34. 34.
    Federal Statistical Office. Bevölkerung Deutschlands bis 2060. 12. koordinierte Bevölkerungsvorausberechnung 2009 [online]. Available from URL: https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/VorausberechnungBevoelkerung/BevoelkerungDeutschland2060Presse5124204099004.pdf [Accessed 2012 Apr 19]
  35. 35.
    Eurostat. Statistical database, Code: tsiem030, 2012 [online]. Available from URL: http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/dataset?p_product_code=TSIEM030 [Accessed 2012 Apr 19]
  36. 36.
    Werblow A, Felder S, Zweifel P. Population ageing and health care expenditure: a school of ‘red herring’? Health Econ 2007; 16(10): 1109–26PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Research Center for Generational ContractsUniversity FreiburgGermany

Personalised recommendations